Krane L Spencer, Laungani Rajesh, Satyanarayana Ramgopal, Kaul Sanjeev, Bhandari Mahendra, Peabody James O, Menon Mani
Vattikuti Urology Institute, Henry Ford Health Systems, Detroit, Michigan 48202, USA.
Urology. 2008 Dec;72(6):1351-5. doi: 10.1016/j.urology.2008.06.057.
Patients requiring chronic anticoagulation therapy (CAT) with warfarin require special attention perioperatively. We retrospectively reviewed our experience of treating patients requiring CAT who underwent robotic-assisted radical prostatectomy (RARP) to evaluate the role of perioperative bridging therapy.
A total of 60 patients receiving cat with warfarin who underwent rarp were identified as having been treated using 1 of 2 protocols: protocol 1, the cessation of CAT 7 days before surgery and its resumption the evening of catheter removal (postoperative day 4-21); or protocol 2, warfarin substituted with perioperative subcutaneous low-molecular-weight heparin, with oral anticoagulation restarted after catheter removal. The decision to use perioperative bridging was made in conjunction with the patient's primary care physician. The peri- and postoperative parameters and complications were compared with a matched control group of 181 contemporary patients who underwent RARP but did not require CAT.
The most common indications for CAT were atrial fibrillation (58%) and recurrent deep vein thrombosis (22%). Compared with the control cohort, the patients with CAT had an increased operative time (189 vs 170 minutes, P = .005) and hospital stay (1.4 vs 1.1 days, P = .004). The estimated blood loss (123.9 vs 146.6 mL, P = .07) and 24-hour change in hemoglobin (2.2 vs 2.3 g/dL, P = .44) were similar. When comparing the 2 protocols, a significantly greater transfusion rate (23% vs 2%, P = .042) occurred with protocol 2, but no increase was seen in the complication or readmission rate. One nonfatal thromboembolic event occurred in 1 patient treated using protocol 1.
The results of our study have shown that RARP can be performed safely in patients requiring CAT, with and without bridging therapy. Patients in protocol 2 had greater transfusion rates, but this did not translate into increased complications or readmissions.
需要使用华法林进行长期抗凝治疗(CAT)的患者在围手术期需要特别关注。我们回顾性分析了我们治疗接受机器人辅助根治性前列腺切除术(RARP)且需要CAT的患者的经验,以评估围手术期桥接治疗的作用。
共有60例接受华法林CAT治疗并接受RARP的患者被确定采用以下两种方案之一进行治疗:方案1,术前7天停止CAT,导尿管拔除当晚(术后第4 - 21天)恢复使用;方案2,围手术期皮下注射低分子肝素替代华法林,导尿管拔除后重新开始口服抗凝治疗。围手术期桥接治疗的决定是与患者的初级保健医生共同做出的。将围手术期和术后参数及并发症与181例同期接受RARP但不需要CAT的匹配对照组患者进行比较。
CAT最常见的适应证是房颤(58%)和复发性深静脉血栓形成(22%)。与对照组相比,接受CAT的患者手术时间延长(189分钟对170分钟,P = 0.005),住院时间延长(1.4天对1.1天,P = 0.004)。估计失血量(123.9毫升对146.6毫升,P = 0.07)和血红蛋白24小时变化(2.2克/分升对2.3克/分升,P = 0.44)相似。比较两种方案时,方案2的输血率显著更高(23%对2%,P = 0.042),但并发症或再入院率未见增加。在1例采用方案1治疗的患者中发生了1例非致命性血栓栓塞事件。
我们的研究结果表明,无论是否进行桥接治疗,RARP均可在需要CAT的患者中安全进行。方案2的患者输血率更高,但这并未转化为并发症或再入院率的增加。